GT Biopharma shares surge 11.14% intraday after submitting IND for B7-H3-targeted solid tumor therapy GTB-5550.

GT Biopharma Inc. surged 11.14% intraday after announcing the submission of an IND application for GTB-5550, a B7-H3-targeted TriKE for solid tumor cancers. The milestone marks the company’s expansion into a larger patient population, with the global solid tumor market estimated at $362 billion. GTB-5550, the first dual nanobody TriKE, is designed for subcutaneous dosing and will enter a Phase 1 basket trial in 2026 across seven metastatic cancers. The news reinforced investor confidence in the company’s pipeline diversification and market potential, while the preliminary $7 million cash balance as of December 2025, extending operations into Q3 2026, alleviated near-term liquidity concerns. These developments align with the stock’s sharp intraday rally, driven by positive sentiment around regulatory progress and therapeutic innovation.